PubRank
Search
About
CT-011 MAb in DLBCL Patients Following ASCT
Clinical Trial ID NCT00532259
PubWeight™ 12.09
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00532259
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
J Clin Oncol
2013
3.77
2
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Clin Cancer Res
2013
3.48
3
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Trends Mol Med
2014
1.59
4
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
J Hematol Oncol
2016
1.12
5
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Int J Mol Sci
2016
0.97
6
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Mol Cancer
2015
0.94
7
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications.
Front Immunol
2015
0.92
Next 100